The company's lead drug candidate is a combination of a p38 MAPK inhibitor and another drug, which aims to provide an effective oral treatment for patients with serious diseases. Kinarus is currently conducting a Phase 2 clinical trial for hospitalized Covid-19 patients, with the goal of reducing mortality and hospital stay duration. Additionally, the company has received regulatory approval for a Phase 2 trial in patients with wet Age-Related Macular Degeneration, a condition that often leads to vision loss. Kinarus aims to improve treatment outcomes by reducing injection frequency and providing additional therapeutic benefits for patients and their caregivers.